Tocilizumab efficacy in COVID-19 patients is associated with respiratory severity-based stages

Melchor Alvarez-Mon; Angel Asunsolo; José Sanz; Benjamin Muñoz; José Alberto Arranz-Caso; Maria Novella Mena; Cristina Hernández-Gutiérrez; Jorge Navarro; Maria Cristina Lozano Duran; Juan Arévalo Serrano; Rocío Henche Sanchez; Lara Bravo Quiroga; Julio Flores Segovia; Marta Garcia Sanchez; Aida Gutierrez Garcia; Ana Pérez; Marta Herrero; Nieves Plana; Daniel Troncoso; Gorjana Rackov; Carlos Martinez-A; Dimitrios Balomenos; for The Medicine-COVID19 HUPA group

doi:10.1101/2021.03.04.21252167

Article Information

doi

https://doi.org/10.1101/2021.03.04.21252167

History

March 9, 2021.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

Melchor Alvarez-Mon, MD1,2,3,4,*,
Angel Asunsolo3,5,6,*,
José Sanz2,7,
Benjamin Muñoz2,7,
José Alberto Arranz-Caso2,7,
Maria Novella Mena7,
Cristina Hernández-Gutiérrez7,
Jorge Navarro7,
Maria Cristina Lozano Duran7,
Juan Arévalo Serrano7,
Rocío Henche Sanchez7,
Lara Bravo Quiroga8,
Julio Flores Segovia8,
Marta Garcia Sanchez7,
Aida Gutierrez Garcia7,
Ana Pérez1,2,
Marta Herrero9,
Nieves Plana3,10,
Daniel Troncoso10,
Gorjana Rackov11,
Carlos Martinez-A11,
Dimitrios Balomenos11,*,§,
for The Medicine-COVID19 HUPA group

¹Internal Medicine Service and Rheumatology-Autoimmunity Service. “Príncipe de Asturias” University Hospital. Alcala de Henares, Madrid. Spain
²Department of Medicine and Medical Specialties. Alcala University. Madrid. Spain
³Ramón y Cajal Health Research Institute
⁴Ciber HyD
⁵Department of Surgery and Medical Social Sciences. Alcala University. Madrid. Spain
⁶Department of Epidemiology & Biostatistics. Graduate School of Public Health and Health Policy, City University of New York, New York, NY, United States
⁷Internal Medicine Service “Príncipe de Asturias” University Hospital. Alcala de Henares, Madrid. Spain
⁸Respiratory Medicine Service “Príncipe de Asturias” University Hospital. Alcala de Henares, Madrid. Spain
⁹Pharmacy Service. “Príncipe de Asturias” University Hospital. Alcala de Henares, Madrid. Spain
¹⁰Preventive Medicine Service.“Príncipe de Asturias” University Hospital. Alcala de Henares, Madrid. Spain
¹¹Department of Immunology and Oncology. National Center for Biotechnology. Spanish National Research Council/CSIC, Madrid. Spain

↵§Corresponding author:
Dr. D Balomenos., Tel (+34) 91 585 5449, Fax (+34) 91 372 0493, email: dbalomenos{at}cnb.csic.es

↵* Drs. M. Alvarez-Mon, A. Asunsolo and D. Balomenos contributed equally to this article.
Author contributions: MAM, DB and CM conceived the main idea. MAM, AA and DB designed the study and analyzed results. DB wrote the manuscript and supervised the data. MAM and AA contributed in writing the manuscript and supervised the data. AA performed statistical analyses. GR analyzed the data and contributed in figure and table elaboration. All other authors supervised treatment of patients and obtained and recorded clinical data.